Connie Hsia, MD
I am a pulmonologist involved with multiple aspects of academic medicine, including clinical and applied basic research, clinical practice, and education. I obtained my MD degree, followed by an internal medicine residency and a pulmonary medicine fellowship at the University of Toronto, Canada. I moved to Dallas, Texas, for a research fellowship in pulmonary physiology, then became a faculty member. As a physician-scientist, my research interests center on the mechanisms of compensatory lung growth and strategies to maximize innate reparative and regenerative potential. With multi-disciplinary collaborators, we combine physiologic, morphometric, imaging, and cellular/molecular biology techniques to elucidate the stimuli of alveolar-capillary regrowth and remodeling and explore new therapeutics to improve outcomes. We developed noninvasive measurements of cardiopulmonary function in humans and animals, quantified lung ultrastructure using CT and MRI in correlation to lung function and injury-repair in clinical disease, and examined molecular mechanisms of lung remodeling and re-growth. In addition to the original investigation, I spearheaded several Thoracic Society Task Forces outlining a) the signals, mechanisms, and limits of lung growth, b) the quantification of ex vivo lung ultrastructure by microscopy, and c) the in vivo imaging-derived metrics relating lung structure to pathophysiology.
My clinical interests center on the granulomatous disease sarcoidosis; I have cared for patients with this diagnosis for many years and maintained an active Clinical Registry. UT Southwestern is a Foundation for Sarcoidosis Research Center of Excellence, and we are a founding member of the Global Sarcoidosis Clinic Alliance. As a subspecialty referral center, many of our patients suffer from multi-system sarcoidosis. We are active in conducting clinical trials and participating in a multi-center NHLBI study to examine biomarkers for predicting sarcoidosis progression and clinical outcomes.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:ATyr PharmaTopic:Contract clinical trialDate added:04/02/2026Date updated:04/02/2026Relationship end date:04/01/2027
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Kinevant biosciencesTopic:Contract clinical trialDate added:04/02/2026Date updated:04/02/2026Relationship end date:12/31/2026
-
Attribution:Spouse or PartnerType of financial relationship:Financial StakeIneligible company:EPOK PharmaceuticalTopic:founder's sharesDate added:04/02/2026Date updated:04/02/2026
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Signify BiioTopic:Planned experimentsDate added:04/02/2026Date updated:04/02/2026
**Disclaimer**
This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.

Facebook
X
LinkedIn
Forward